Study summary · research use only
Mitochondrial uncoupler BAM15 enhances the function of CD7CAR-T(CD7-) cells and reduces the release of cytokines for the therapy of T-cell malignancies
Plain-language summary
Paraphrased from the published abstract below — not a verdict on whether anything works.
In this study using human peripheral blood cells and xenograft mouse models, the authors generated CD7CAR-T(CD7-) cells from CD7-negative T cells modified with a CD7-targeted CAR construct, for T-cell malignancies such as T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphomas. Cytotoxic activity against CD7-positive T-cell malignancies was assessed in vitro and in xenograft mice. The authors identified BAM15, a mitochondrial uncoupling agent, and reported that BAM15 enhanced cytotoxic function of CD7CAR-T(CD7-) cells in a concentration-dependent manner while reducing cytokine release. At low concentrations (2.5μM, 1 μM and 0.5 μM), BAM15 was associated with improved antitumor activity at suboptimal effector-to-target ratios (E:T = 1:1 and 1:2), reduced IL-6 and TNFα, and less inflammatory cell infiltration in lung and liver.
Abstract
Traditional therapies for relapsed/refractory T-cell malignancies, such as T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphomas, have limited efficacy. Chimeric antigen receptor T-cell (CAR-T) therapy has shown potential in treating hematologic malignancies, but challenges such as tumor immune evasion, CAR-T resistance, and cytokine release syndrome (CRS) hinder its clinical application. In this study, we generated CD7CAR-TCD7- cells by modifying naturally occurring CD7 negative T cells from human peripheral blood with a novel CD7 targeted CAR construct. The cytotoxic efficacy of CD7CAR-TCD7- cells against CD7 positive T cell malignancies was assessed through in vitro experiments and xenograft mouse models. To address CAR-T therapy limitations, we identified BAM15, a mitochondrial uncoupling agent, from a small molecule library. BAM15 enhanced the cytotoxic function of CD7CAR-TCD7- cells in a concentration-dependent manner while reducing cytokine release profile in both cellular assays and xenograft models. Notably, at low concentrations (2.5μM, 1 μM and 0.5 μM), BAM15 improved antitumor efficacy at suboptimal effector-to-target ratios (E:T = 1:1 and 1:2), reduced inflammatory cytokines like IL-6 and TNFα, and alleviated inflammatory cell infiltration in lung and liver. This study confirms the feasibility of constructing CD7CAR-TCD7- cells from CD7- T cells and first reveals the synergistic effects of BAM15 on CD7CAR-TCD7- cells, for overcoming dose limitations and CRS of CAR-T therapy, and providing a novel strategy for T-cell malignancies.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow the citation to its source and read it yourself. Research use only.